Combating the fungal pandemic

BlueTile combats the fungal global pandemic

Providing Missing Piece in ICU Critical Care

The alarming statistics shown above reveal a silent crisis escalating in ICUs worldwide. Invasive fungal infections strike the most vulnerable patients, doctors are battling these devastating, multidrug-resistant Candida and Aspergillus strains using an outdated arsenal that is increasingly ineffective, often toxic, and/or restricted by critical drug interactions.

BlueTile develops the missing piece to solve this complex puzzle. Our potent intravenous antifungal empowers ICU doctors to successfully cure life-threatening infections by providing a first-in-class medicine that is uniquely effective against both resistant Candida and Aspergillus species, offering a superior safety profile with high tissue penetration and/or minimal drug-to-drug interference.